Skip to content
Clinical Trials – home

H2-Receptor Antagonists: A Comprehensive Guide for Patients

2 / 4
trials open to patients / all trials
9+
Countries

In short

This article explores the use of H2-Receptor Antagonists in various clinical trials for cancer treatment. These trials investigate the efficacy and safety of H2-Receptor Antagonists, often in combination with other drugs, for different types of cancer including lung cancer, breast cancer, gastric cancer, urothelial carcinoma, and cervical cancer. The studies aim to evaluate the drug's potential in improving patient outcomes and quality of life.

What are H2-Receptor Antagonists?

H2-Receptor Antagonists, also known as H2 blockers, are a class of medications primarily used to treat conditions related to excess stomach acid. These drugs work by blocking histamine receptors in the stomach, which helps reduce the production of stomach acid.

Medical Conditions Treated

H2-Receptor Antagonists are commonly used to treat several gastrointestinal conditions, including:

  • Gastroesophageal reflux disease (GERD): A condition where stomach acid frequently flows back into the esophagus
  • Peptic ulcers: Open sores that develop on the inside lining of the stomach and upper small intestine
  • Dyspepsia: A term for stomach discomfort or indigestion
  • Zollinger-Ellison syndrome: A rare condition that causes tumors in the pancreas or duodenum, leading to increased stomach acid production

Interestingly, recent clinical trials are exploring the potential use of H2-Receptor Antagonists in combination with other drugs for treating various types of cancer. These include non-small cell lung cancer (NSCLC), breast cancer, gastric cancer, and cervical cancer.

How H2-Receptor Antagonists Work

H2-Receptor Antagonists work by blocking the action of histamine on the H2 receptors of the stomach's parietal cells. Histamine normally stimulates these cells to produce stomach acid. By blocking this action, H2-Receptor Antagonists reduce the amount of acid produced by the stomach, which can help alleviate symptoms and promote healing in conditions related to excess stomach acid.

Administration and Dosage

H2-Receptor Antagonists are typically available in the following forms:

  • Oral tablets or capsules
  • Liquid formulations
  • Intravenous (IV) solutions (in hospital settings)

The dosage and duration of treatment can vary depending on the specific condition being treated and the individual patient's response. It's crucial to follow your healthcare provider's instructions or the directions on the product label carefully.

Potential Side Effects

While H2-Receptor Antagonists are generally well-tolerated, they can cause side effects in some people. Common side effects may include:

  • Headache
  • Dizziness
  • Diarrhea or constipation
  • Nausea or vomiting
  • Fatigue

Serious side effects are rare but can include liver problems, changes in heart rhythm, and an increased risk of certain infections. If you experience any unusual or severe side effects, contact your healthcare provider immediately.

Ongoing Research

Recent clinical trials are investigating the potential use of H2-Receptor Antagonists in combination with other drugs for cancer treatment. These studies are exploring their efficacy in various types of cancer:

  • Non-small cell lung cancer (NSCLC): A study is evaluating the combination of an H2-Receptor Antagonist with pembrolizumab in patients with resectable stage II to IIIB NSCLC.
  • Breast cancer: Research is being conducted on the use of H2-Receptor Antagonists in combination with pembrolizumab for hormone receptor-positive breast cancer.
  • Gastric cancer: A clinical trial is comparing an H2-Receptor Antagonist to standard treatment in patients with advanced or metastatic gastric adenocarcinoma.
  • Cervical cancer: Researchers are studying the efficacy of an H2-Receptor Antagonist as a second-line treatment for recurrent or metastatic cervical cancer.

It's important to note that these are ongoing studies, and the use of H2-Receptor Antagonists in cancer treatment is not yet approved or established. Patients should not use these medications for cancer treatment outside of clinical trials and without medical supervision.

Conclusion

H2-Receptor Antagonists are valuable medications primarily used to treat conditions related to excess stomach acid. They work by reducing acid production in the stomach, providing relief from symptoms associated with conditions like GERD and peptic ulcers. While generally safe and effective, it's important to use these medications as directed and be aware of potential side effects. Ongoing research is exploring new potential uses for these drugs, particularly in cancer treatment, but more studies are needed to establish their efficacy in these areas.

Questions people often ask

Conditions where H2-Receptor Antagonist is being studied

Each condition opens its own overview and trial list

Trials with H2-Receptor Antagonist

Recruiting trials first

See all 4 →
Quick filters
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).